Lonza Group H1 2024 Performance Well On Track to Deliver Full-Year Outlook: Sales Up 1.8% CER and 29.2% CORE EBITDA Margin
Source: EQS
Ad hoc announcement pursuant to Art. 53 LR
Group Financial Summary
For more details on performance and financials, please refer to the Half-Year 2024 Presentation, Half-Year 2024 Report and Alternative Performance Measures (APM) 2024 Report.
1 Sales growth figures, expressed as a percentage (%), are at Constant Exchange Rate (CER) About Lonza Lonza is one of the world’s largest healthcare manufacturing organizations. Working across five continents, our global community of around 18,000 colleagues helps pharmaceutical, biotech and nutrition companies to bring their treatments to market. United by our vision to bring any therapy to life, we support our customers with a combination of technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work enables our customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from life-saving and life-enhancing treatments. Our business is structured to meet our customers' complex needs across four divisions: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients. Our company generated sales of Lonza Contact Details Head of
End of Inside Information |
Language: | English |
Company: | |
Münchensteinerstrasse 38 | |
4052 |
|
Phone: | +4161 316 81 11 |
Internet: | www.lonza.com |
ISIN: | CH0013841017 |
Valor: | 1384101 |
Listed: | |
EQS News ID: | 1953479 |
End of Announcement |
|
1953479 25-Jul-